Kestrel Therapeutics Inc. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described GTPase KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) and/or (G13D mutant) inhibitors reported to be useful for the treatment of cancer.

Newave Pharmaceutical LLC has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Gilead Sciences Inc. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Hyku Biosciences Inc. has synthesized GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Sanofi SA has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Silexon Intelligent Technology Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized son of sevenless homolog 1 (SOS1) and GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.